Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Toussia-Cohen Sharon — Protalix BioTherapeutics, Inc. insider: 1 transactions · InsiderLens

Home / Insiders / Toussia-Cohen Sharon

Toussia-Cohen Sharon

Director at Protalix BioTherapeutics, Inc. · on record since Jan 5, 2007
10% owner at Protalix BioTherapeutics, Inc. · on record since Jan 5, 2007

Insider trading activity of Toussia-Cohen Sharon

Transactions on record: 1; since Jan 5, 2007

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Jan 5, 2007

Figures computed from official regulatory filings — methodology.

Companies where Toussia-Cohen Sharon has traded

Protalix BioTherapeutics, Inc.1 tx · Jan 5, 2007

Track record of Toussia-Cohen Sharon

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Toussia-Cohen Sharon

Co-insiders of Toussia-Cohen Sharon

Akirov AlfredProtalix BioTherapeutics, Inc.
Almon Einat BrillProtalix BioTherapeutics, Inc.
Altschuler StevenProtalix BioTherapeutics, Inc.
Aviezer DavidProtalix BioTherapeutics, Inc.
Bar-Shalev AmosProtalix BioTherapeutics, Inc.
Bashan DrorProtalix BioTherapeutics, Inc.
Beck Joanne T.Protalix BioTherapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Ben Zvi ShmuelProtalix BioTherapeutics, Inc.

Bio-Cell LtdProtalix BioTherapeutics, Inc.

Boudes Pol FProtalix BioTherapeutics, Inc.

Bronfeld ZeevProtalix BioTherapeutics, Inc.

Buchris Pinhas BarelProtalix BioTherapeutics, Inc.

Camber Capital Management LLCProtalix BioTherapeutics, Inc.

Curnutte John TProtalix BioTherapeutics, Inc.

Dexcel Pharma Technologies Ltd.Protalix BioTherapeutics, Inc.

Dunoyer MarcProtalix BioTherapeutics, Inc.

Ellis JonProtalix BioTherapeutics, Inc.

Elze ChristianProtalix BioTherapeutics, Inc.

FLORES JAMES CProtalix BioTherapeutics, Inc.

FMR LLCProtalix BioTherapeutics, Inc.

Forster EliotProtalix BioTherapeutics, Inc.

Frost Gamma Investment TrustProtalix BioTherapeutics, Inc.

FROST PHILLIP MD ET ALProtalix BioTherapeutics, Inc.

Gaspar BobbyProtalix BioTherapeutics, Inc.

GERAGHTY JAMES AProtalix BioTherapeutics, Inc.

GLAXOSMITHKLINE PLCProtalix BioTherapeutics, Inc.

Granot DavidProtalix BioTherapeutics, Inc.

Gross Yodfat HarelProtalix BioTherapeutics, Inc.

Hayon YaelProtalix BioTherapeutics, Inc.

HITCHCOCK WILLIAM MProtalix BioTherapeutics, Inc.

HSIAO JANE PH DProtalix BioTherapeutics, Inc.

Hurvitz EliProtalix BioTherapeutics, Inc.

Katz IftahProtalix BioTherapeutics, Inc.

Kolchinsky PeterProtalix BioTherapeutics, Inc.

Kornberg Roger D.Protalix BioTherapeutics, Inc.

Lauterbach Sandra LeighProtalix BioTherapeutics, Inc.

Lockshin CurtisProtalix BioTherapeutics, Inc.

Mamlok GiladProtalix BioTherapeutics, Inc.

Manor MosheProtalix BioTherapeutics, Inc.

Marathon Investments Ltd.Protalix BioTherapeutics, Inc.

Melincoff Gwen AProtalix BioTherapeutics, Inc.

Naos YaronProtalix BioTherapeutics, Inc.

OMALLEY WILLIAM CProtalix BioTherapeutics, Inc.

Oren DanProtalix BioTherapeutics, Inc.

Palash TzviProtalix BioTherapeutics, Inc.

RA Capital Biotech Fund LPProtalix BioTherapeutics, Inc.

RA CAPITAL MANAGEMENT, LLCProtalix BioTherapeutics, Inc.

RAYMOND JOHN TProtalix BioTherapeutics, Inc.

Rothera MarkProtalix BioTherapeutics, Inc.

Rowland Charles A JrProtalix BioTherapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
Protalix BioTherapeutics, Inc.	Jan 5, 2007	Award	6,556,381	—	—	SEC